Industry News
BRCA1 gene mutation linked to fewer eggs in ovaries
4/20/2016
Women with the BRCA1 mutation may have fewer eggs in their ovaries, since they have a lower level of the hormone AMH, which is a predictor of ovarian reserve.
NanoString Technologies, Inc, a provider of life science tools for translational research and molecular diagnostic products, has presented the first proof-of-concept data from its novel multiplexed...
Merkel cell carcinoma patients who received pembrolizumab often had durable responses
4/20/2016
Study shows patients with advanced MCC treated with the experimental immunotherapy drug had longer responses than is typical for standard chemotherapy.
Scientists propose treatment for severe lung diseases
4/20/2016
Acute lung injury triggered by infectious diseases, newborn congenital lung disorders.
ANGLE plc, the specialist medtech company, is delighted to announce that the results of the University of Southern California (USC) Norris Comprehensive Cancer Center's ongoing work with ANGLE's...
Combination therapy incorporating 3 new agents shows promise as treatment for aggressive lymphoma
4/20/2016
New research from Roswell Park Cancer Institute (RPCI) shows that promising cancer drugs used in combination can have significant therapeutic impact on a particularly aggressive subtype of diffuse...
Rare pediatric cancer infantile fibrosarcoma (IFS) successfully treated with new targeted therapy
4/20/2016
Infant's tumor regression shows promise for experimental treatment. When a baby's life was threatened by a rare pediatric cancer that would not respond to surgery or chemotherapy, doctors at...
Researchers at Roswell Park Cancer Institute (RPCI), in collaboration with investigators from the cooperative group SWOG, have found that use of multivitamins prior to diagnosis may reduce the risk...
New technology quantifies effects of prostate tumor laser ablation
4/20/2016
Effort to understand risks of treatment, and prognostic clues to long-term outcomes. Prostate cancers are either low-grade, low-risk forms that may be monitored but otherwise untreated.
A preclinical study of lenvatinib plus everolimus1 demonstrates enhanced inhibition of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF)-induced angiogenesis than for...